Detalhe da pesquisa
1.
Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis.
Bioorg Med Chem
; 49: 116424, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626901
2.
Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives.
Bioorg Med Chem Lett
; 26(4): 1209-13, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26794040
3.
Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives.
Bioorg Med Chem Lett
; 25(20): 4387-92, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384288
4.
Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.
Bioorg Med Chem Lett
; 25(7): 1479-82, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25746814
5.
Discovery of a potent, orally available dual CysLT1 and CysLT2 antagonist with dicarboxylic acid.
Bioorg Med Chem
; 23(9): 2079-97, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25800431
6.
Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly.
ACS Chem Neurosci
; 11(10): 1482-1494, 2020 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315148
7.
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.
J Med Chem
; 58(15): 6093-113, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26200813
8.
Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.
ACS Med Chem Lett
; 5(11): 1230-4, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25408836